Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias

Table 1 Demographic characteristics of the study cohort

	Number	Female, n (%)	Age at CSF/plasma collection, years	Time from onset to CSF/plasma collection, months
FTD^#	59	34 (57.6)^a,b	62.9 (8.9)^c–f	34.3 (33.5)^a,e
PSP	31	11 (35.5)^g	69.2 (10.2)^h	51.5 (33.1)ⁱ
CBS	29	18 (62.1)^b	71.3 (7.2)^h	43.2 (37.4)
DLB	49	14 (28.6)^f,j	73.7 (6.7)^h,i,k	65.3 (53.9)^f,i
AD	97	54 (55.7)	67.8 (9.3)^h	41.7 (34.9)ⁱ
SNAP	51	25 (49.0)	66.2 (9.5)	26.6 (25.1)
HC	60	26 (43.3)	61.7 (4.9)	–

Continuous variables are expressed as mean (SD)
FTD frontotemporal dementia, PSP progressive supranuclear palsy, CBS corticobasal syndrome, DLB dementia with Lewy bodies, AD Alzheimer disease, SNAP suspected non-AD physiopathology, HC healthy controls
^avs. PSP ≤ 0.05
^bvs. DLB ≤ 0.01
^cvs. PSP ≤ 0.01
^dvs. CBS ≤ 0.001
^evs. DLB ≤ 0.001
^fvs. AD ≤ 0.01
^gvs. CBS ≤ 0.05
^hvs. HC ≤ 0.001
ⁱvs. SNAP ≤ 0.001
^jvs. SNAP ≤ 0.05
^kAD ≤ 0.001
^#Included cases with FTD + ALS and FTD + parkinsonism

ISSN: 1758-9193